- PDF Free Download

Size: px

Start display at page:

Download ""

まいかすみだ
5 years ago
Views:

1 Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 1 Tetsuya Yamamoto

3 Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 3

Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 5 marone, l'-oh benzbromarone, 1' ketone benzbromarone, di-oh benzbromarone0)it W.tt h. t. L OSiff*-,Tf t,--jk7w.

5 Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 5 marone, l'-oh benzbromarone, 1' ketone benzbromarone, di-oh benzbromarone0)it W.tt h. t. L OSiff*-,Tf t,--jk7w.a Ftlt% debromobenzbromaronefcpbennzarone ritit lift. is 0'8). I IL-4KP] hcyp2c9 3M0 iiria-1/011 f?, 6 :in vitro peroxysome proliferator-activated receptor a (PPAR a) (fkie) F9I ts, VA!Tr- 't)-vat' 0).-e a Is fifi 1/1--CV,1. benzbromarone probenecid F-4 l r_oxypurino10 'ATM 'fat benzbromarone allopurinol fj'hil [4- V: 031, 6 oxypurinol0 &FP t (Dg-F b ±.Naa <, %FEW& ZW61PILTT lif 7:c. or) L /Er-' 91 TA.)X V.:.ts fjfiti*ahl < M.45k Fala,14iRoiNIV: < ilatifsprodmwitcw--ykame AILW, '11-4.(DiglilL7:cZ. fif <," 66 a t, WA- trc toz. < 1H 2 )i/ 0-E ITKI Mt -h-5±.:(53'iatfrhg,w kr..-wepongfia_llfztc-jce3koph (1:-t t < itp6dig1 ft <, WAVI-C-D :/ xt/ on-4 < ts z oye, 7 )1/ t fl% (SW, NAIJ ) benzbromarone, o) ph 6-7 (,:i*'d :7) r-t 6 r-benzbromarone0r-v-vtioltatacof, f7r04 fcp P7t NM L, tg..c/to=1:171701p1vir(1)10 bu,k101.1t, 10114a116,-'cDK 1:1=1W 14ifi ir i*m mg/d1AT LffilL50k NA, Wi

7 Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 7

8 1 ) Gutman AB, Boots RH, Shemin D et al : Uric acid metabolism and gout. Am J Med 9 : , ) Burns JJ, Yu T-F, Ritterband A et al : A potent new uricosuric agent, the sulfoxide metabolite of the phenybutazone analogue. G-25671, J Pharmacol Exp Ther 119 : , ) Rundles RW, Wyngaarden JB, Hitchings GH et al : Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hypertension and gout. Trans Assoc Am Physicians 76 : , 1963.

9 Gout and Nucleic Acid Metabolism Vol.27 No.1 (2003) 9 5) Elion GB, Callahan SW, Nathan H et al : Potent action by inhibition of drug degradation 6-substituted purines and xanthine oxidase. Biochem Pharmacol 12 : 85-93, ) Y-T-F, Gutman AB : Effect of allopurinol (4- hydroxy-pyrazolo-3,4-d pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 37 : , ) Delbarre F, Auscher C, Olivier JL et al : [Treatment of hyperuricemic and gouty patients with derivatives of benzofuran] Sem Hop. 43 : , ) Komoriya K, Osada Y, Hasegawa M et al : Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6720 in chimpanzees. Eur J Pharmacol. 250 : , ) Brant JM Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin J Oncol Nurs. 6 : 12-16, ) Kelley WN, Beardmore TD : Allopurinol: alteration in pyrimidine metabolism in man. Science 169 : , ) Elion GB, Yu TF, Gutman AB et al : Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 45:69-77, ) Tjandramaga TB, Cucinell SA, Israili ZH et al : Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology 8 : , ) Vesell ES, Passananti GT, Greene FE : Impairment of drug metabolism in man by allopurinol and nortriptyline. N Engl J Med 283 : , ) Elion GB, Callahan SW, Rundles RW et al : Relationship between metabolic fates and antitumor activities of thiopurines. Cancer Res 23: , ) Grace ND, Greenwald MA, Greenberg MS : Effect of allopurinol on iron mobilization. Gastroenterology 59 : , ) Enomoto A, Kimura H, Chairoungdua A et al : Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417 (6887) : , ) Guarino AM, Schanker LS : Biliary excretion of probenecid and its glucuronide. J Pharmacol Exp Ther 164 : , ) Kates RE, Tozer TN, Sorby DL : Increased methotrexate toxicity due to concurrent probenecid administration. Biochem Pharmacol 25 : , ) Jenkins CS, Packham MA, Guccione MA et al : Modification of platelet adherence to proteincoated surfaces. J Lab Clin Med 81 : , ) Ali M, McDonald JW : Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J Lab Clin Med 89 : , ) The Anturane Reinfarction Trial Research Group : Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302 : , ) Pui CH, Relling MV, Lascombes F et al : Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 11 : , ) Nakashima M, Uematsu T, Kosuge K et al : Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42 : , ) Yamamoto T, Moriwaki Y, Takahashi S et al : Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxy-

10 purinol and purine bases. J Rheumatol 27 : , ) Fruchart JC, Staels B, Duriez P : The role of fibric acids in atherosclerosis. Curr Atheroscler Rep 3 : 83-92, ) Yamamoto T, Moriwaki Y, Takahashi S et al : Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 28 : , 2001.

437“ƒ

437“ƒ et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer